🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Aerosolized, Recombinant Alpha 1-Antitrypsin

    Takeda

    Alpha1-antitrypsin Deficiency

    phase 2 small molecule completed

    2 trials

  2. Aes-103

    Takeda

    Sickle Cell Disease

    phase 2 small molecule completed

    2 trials

  3. Aldesleukin

    United Therapeutics Europe Ltd

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  4. Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cells (MSC) ectopically expressing CXCR4 and IL10

    The George Institute

    Patients who have developed acute GVHD refractory to corticosteroids and ruxolitinib or that are not eligible to receive ruxolitinib

    phase 2 small molecule active

    1 trial

  5. Allogeneic Cardiosphere-Derived Cells (CAP-1002)

    CAPRICOR THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    2 trials

  6. Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Adults diagnosed with SJS-TEN with at least 10% of body surface area involved

    phase 2 small molecule active

    1 trial

  7. Allogenic expanded Natural Killer Cells (AlloNK1)

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 mab active

    1 trial

  8. Almonertinib 110 MG

    Chinese University of Hong Kong

    Rare Tumor

    phase 2 small molecule active

    1 trial

  9. AloCelyvir

    The George Institute

    mEtastatic Uveal Melanoma

    phase 2 small molecule active

    1 trial

  10. Alphagan 2 mg/ml colirio en solución, Brimonidine Tartrate 0.2% w/v Eye Drops., Mirvetuximab Soravtansine, Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension

    AbbVie Deutschland GmbH & Co. KG

    Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

    phase 2 small molecule active

    1 trial

  11. Alunbrig 30 mg film-coated tablets, CRIZOTINIB, LORLATINIB, Zykadia 150 mg hard capsules, ALECTINIB

    The George Institute

    locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC

    phase 2 small molecule active

    1 trial

  12. Alvelestat

    Mereo BioPharma Group plc

    Covid19

    phase 2 small molecule completed

    1 trial

  13. Alvelestat (MPH966)

    Mereo BioPharma Group plc

    Alpha-1 Antitrypsin Deficiency (AATD)

    phase 2 small molecule completed

    1 trial

  14. Alxn1920 placebo product, ALXN1920

    Alexion Europe SAS

    Primary Mebranous Nephropathy (PMN)

    phase 2 small molecule active

    1 trial

  15. Amifampridine Phosphate 10 MG Oral Tablet

    CATALYST PHARMACEUTICALS, INC.

    Spinal Muscular Atrophy Type 3

    phase 2 small molecule terminated

    1 trial

  16. Amikacin (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia

    phase 2 small molecule completed

    1 trial

  17. Amikacin inhalation solution (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia

    phase 2 small molecule completed

    1 trial

  18. Amimox 500 mg filmdragerade tabletter, Kåvepenin 800 mg filmdragerade tabletter

    The George Institute

    Need of Oral bone augmentation

    phase 2 small molecule active

    1 trial

  19. Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis

    phase 2 small molecule active

    1 trial

  20. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi-aventis Healthcare Pty Ltd

    Alopecia areata

    phase 2 small molecule active

    1 trial

  21. Amlitelimab, Amlitelimab matching placebo to test product

    Sanofi-aventis Healthcare Pty Ltd

    Coeliac disease

    phase 2 small molecule active

    1 trial

  22. Amlitelimab, Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 small molecule active

    1 trial

  23. Amyvid 1900 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, 0.9% (w/v) sodium chloride (Normal Saline), VIZAMYL 400 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  24. Amyvid 800 MBq/mL solution for injection, ACU193 matching Placebo, Neuraceq 300 MBq/mL solution for injection, ACU193, VIZAMYL 400 MBq/mL solution for injection

    Acumen Pharmaceuticals

    Early Alzheimer’s Disease (Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources